Active substance
Theophylline
- SFDA 13
- US FDA 135
- Health Canada 6
- US price lines 5
- NHS prices 3
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| RIAPHYLLIN 60MG/5ML SYRUP | 12 mg/ml | Syrup · Oral use | 1 Bottle | SAR 18.65 | Generic · Prescription | RIYADH PHARMA | Valid |
| THEO-DUR TAB 200MG | 200 mg | Prolonged-release tablet · Oral use | 30 Blister | SAR 12.85 | Generic · Prescription | RECORDATI | Valid |
| THEO-DUR TAB 300MG | 300 mg | Prolonged-release tablet · Oral use | 30 Blister | SAR 15.55 | Generic · Prescription | RECORDATI | Valid |
| AVOLEN 60MG-5ML SYRUP | 12 mg/ml | Syrup · Oral use | 1 Bottle | SAR 8.30 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Withdrawn by MAH · Not Marketed |
| AVOLEN S.R TABLET | 300 mg | Tablet · Oral use | 30 Blister | SAR 15.40 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Withdrawn by MAH · Not Marketed |
| EUPHYLLIN AMP 0.24GM-10ML I.V | 24 mg/ml | Injection · Intravenous use | 5 Ampoule | SAR 14.15 | NCE · Prescription | NYCOMED | Withdrawn by MAH · Not Marketed |
| EUPHYLLINE RETARD C.TAB 250MG | 250 mg | Film-coated tablet · Oral use | 20 Blister | SAR 22.45 | NCE · Prescription | TAKEDA GMBH | Withdrawn by MAH · Not Marketed |
| EUPHYLLINE RTD.MITE C.TAB 175MG | 175 mg | Coated tablet · Oral use | 20 Blister | SAR 17.40 | NCE · Prescription | NYCOMED | Withdrawn by MAH · Not Marketed |
| RIAPHYLLIN 300MG SR TABLET | 300 mg | Prolonged-release tablet · Oral use | 30 Blister | SAR 17.15 | Generic · Prescription | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
| THEOPHAR 100 MG S.R CAPSULES | 100 mg | Prolonged-release capsule · Oral use | 30 Blister | SAR 4.50 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Withdrawn by MAH · Not Marketed |
| THEOPHAR 200 MG S.R CAPSULES | 200 mg | Prolonged-release capsule · Oral use | 20 Blister | SAR 4.50 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Withdrawn by MAH · Not Marketed |
| THEOPHAR 300 MG S.R CAPSULES | 300 mg | Prolonged-release capsule · Oral use | 10 Blister | SAR 4.50 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Withdrawn by MAH · Not Marketed |
| THEOPHAR 60MG-5ML SYRUP | 12 mg/ml | Syrup · Oral use | 1 Bottle | SAR 8.30 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
BRADYCARDIA; CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD); SICKLE CELL DISEASE - ACS MANAGEMENT
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| THEOPHYLLINE | 300MG; 100MG; 200MG; 450MG | tablet, extended release · oral | NOSTRUM PHARMS LLC | Prescription | 11 Jan 1983 |
| THEO-24 | 200MG; 100MG; 300MG; 400MG | capsule, extended release · oral | ENDO OPERATIONS | Prescription | 22 Aug 1983 |
| THEOPHYLLINE | 300MG | tablet, extended release · oral | HERITAGE PHARMA AVET | Prescription | 30 Apr 1990 |
| THEOPHYLLINE | 450MG | tablet, extended release · oral | HERITAGE PHARMA AVET | Prescription | 9 Nov 1992 |
| THEOPHYLLINE | 400MG | tablet, extended release · oral | RHODES PHARMS | Prescription | 15 Apr 1996 |
| THEOPHYLLINE | 600MG; 400MG | tablet, extended release · oral | MPP PHARMA | Prescription | 21 Apr 2006 |
| THEOPHYLLINE | 400MG; 600MG | tablet, extended release · oral | GLENMARK PHARMS LTD | Prescription | 13 Jul 2010 |
| THEOPHYLLINE | 300MG; 450MG | tablet, extended release · oral | ALEMBIC | Prescription | 27 Oct 2010 |
| THEOPHYLLINE | 80MG/15ML | solution · oral | CHARTWELL MOLECULAR | Prescription | 13 Apr 2011 |
| THEOPHYLLINE | 80MG/15ML | solution · oral | TRIS PHARMA INC | Prescription | 15 Jun 2012 |
| THEOPHYLLINE | 80MG/15ML | solution, elixir · oral | PHARM ASSOC | Prescription | 16 Dec 2016 |
| THEOPHYLLINE | 300MG; 450MG | tablet, extended release · oral | GLENMARK PHARMS LTD | Prescription | 3 Jun 2021 |
| THEOPHYLLINE | 300MG; 450MG | tablet, extended release · oral | TEVA PHARMS INC | Prescription | 12 Oct 2022 |
| THEOPHYLLINE | 300MG; 450MG | tablet, extended release · oral | VELZEN PHARMA PVT | Prescription | 30 Jan 2023 |
| THEOPHYLLINE | 300MG; 450MG | tablet, extended release · oral | AMNEAL | Prescription | 20 Mar 2023 |
| THEOPHYLLINE | 300MG; 450MG | tablet, extended release · oral | BIONPHARMA | Prescription | 26 Apr 2023 |
| THEOPHYLLINE | 300MG; 450MG | tablet, extended release · oral | ANNORA PHARMA | Prescription | 8 Sep 2023 |
| THEOPHYLLINE | 300MG; 450MG | tablet, extended release · oral | HARMAN FINOCHEM | Prescription | 24 Oct 2023 |
| THEOPHYLLINE | 300MG; 450MG | tablet, extended release · oral | ZYDUS LIFESCIENCES | Prescription | 21 May 2024 |
| THEOPHYLLINE | 300MG; 450MG | tablet, extended release · oral | STRIDES PHARMA | Prescription | 5 Sep 2024 |
| LANOPHYLLIN | 80MG/15ML | elixir · oral | LANNETT | Discontinued | 26 Jul 1976 |
| ELIXOPHYLLIN | 80MG/15ML | solution, elixir · oral | SOLIS PHARMS | Discontinued | 26 Jan 1979 |
| THEOPHYLLINE | 80MG/15ML | elixir · oral | HALSEY | Discontinued | 8 Feb 1979 |
| THEOPHYLLINE | 80MG/15ML | elixir · oral | PRECISION DOSE | Discontinued | 16 Mar 1979 |
| THEOLAIR | 80MG/15ML | solution · oral | 3M | Discontinued | 26 Mar 1979 |
110 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| AA-THEO LA | 00692689 | 100 MG | TABLET (EXTENDED-RELEASE) · ORAL | AA PHARMA INC |
| AA-THEO LA | 00692697 | 200 MG | TABLET (EXTENDED-RELEASE) · ORAL | AA PHARMA INC |
| AA-THEO LA | 00692700 | 300 MG | TABLET (EXTENDED-RELEASE) · ORAL | AA PHARMA INC |
| ELIXIR DE THEOPHYLLINE | 00627410 | 80 MG / 15 ML | ELIXIR · ORAL | LABORATOIRE ATLAS INC |
| THEO ER | 02360101 | 400 MG | TABLET (EXTENDED-RELEASE) · ORAL | AA PHARMA INC |
| THEO ER | 02360128 | 600 MG | TABLET (EXTENDED-RELEASE) · ORAL | AA PHARMA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | THEOPHYLLINE 80 MG/15 ML SOLN | $0.11183 | per ML | 19 Aug 2026 |
| US NADAC | THEOPHYLLINE ER 300 MG TABLET | $0.32954 | per EA | 23 Sep 2026 |
| US NADAC | THEOPHYLLINE ER 400 MG TABLET | $0.99526 | per EA | 23 Sep 2026 |
| US NADAC | THEOPHYLLINE ER 450 MG TABLET | $1.09918 | per EA | 23 Sep 2026 |
| US NADAC | THEOPHYLLINE ER 600 MG TABLET | $1.39516 | per EA | 14 Jan 2026 |
| NHS Drug Tariff | Theophylline 200mg modified-release tablets | £35.65 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Theophylline 300mg modified-release tablets | £35.65 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Theophylline 400mg modified-release tablets | £35.65 | 56 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Combinations containing Theophylline
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.